Dentsply Sirona (XRAY) stock trades down, here is why
Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut suggest short‑term pressure on the stock, but the company’s long‑term market position remains strong.
Market read
Earnings disappointment directly impacts XRAY and may influence the dental‑equipment sector.
What to watch
Potential cost‑saving initiatives and upcoming product launches are not reflected in the current guidance.
Background
Dentsply Sirona reported Q3 2026 results with a GAAP loss and reduced FY guidance, leading to a 7% share decline.
Ticker impact
Q3 2026 GAAP loss and lowered full‑year guidance caused a 7% drop in the stock.
likely further downside as investors price in weaker outlook
The company posted a GAAP loss of $0.01 per share and cut FY2026 sales to $3.5 bn, prompting a 7% sell‑off.
Market effects
Dental and broader medical device sector may see heightened scrutiny on margins.
U.S. healthcare stocks could face modest pullback.
Limited to investors tracking U.S. listed health‑care equities.
Counterpoint
The price dip may present a buying opportunity if the market overreacts to a modest loss.
Key entities
- companyDentsply Sirona
Dental products manufacturer listed on NASDAQ under XRAY.
